Sun Pharma Q2 FY26 Results: Strong Growth in India, Margins Under Watch

Key Highlights: Revenue: ₹14,405 crore, up 8.6% YoY, led by strong growth in domestic and specialty businesses. Net Profit: ₹3,118 crore, up 2.6% YoY, slightly below revenue growth due to margin pressure. India Business: Up 11% YoY, driven by chronic therapies and new launches. Global Specialty Portfolio: Grew 16% YoY to ~$333 million, a key long-term growth driver. US Generics: Revenue declined 4.1% YoY to ~$496 million amid pricing pressure and competition. Key Insights: Sun Pharma continues to benefit from its diversified portfolio — strong domestic growth offsets weakness in US generics. Expansion in specialty and branded formulations helps sustain topline momentum. However, rising marketing and R&D expenses are weighing on profitability in the near term. Management Commentary: Management emphasized continued focus on specialty product launches in the US and steady growth in India. Cost optimization and pipeline expansion remain priorities. What to Watch: Margin trajectory as high-value specialty products scale up. Pricing trends in US generics. R&D pipeline progress in dermatology and oncology. Regulatory environment in key markets. Investor Takeaway: Sun Pharma remains a leader in India’s pharma space, balancing stable domestic strength with global expansion. While near-term profit growth is modest, its specialty strategy and innovation-led focus keep the long-term outlook positive.